Trial Profile
AA Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ravulizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Biomarker; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 17 Jun 2022 Results of pooled analysis assessing long-term complement inhibition and survival outcomes of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria from phase 1b, 2 and 3 trials (103 [NCT02598583], 201 [NCT02605993], 301 [NCT02946463] and 302 [NCT03056040]) with up to 4 years of open-label extension, presented at the 27th Congress of the European Haematology Association.
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 This trial has been completed in Sweden (End Date: 12 Jan 2022), according to European Clinical Trials Database record.